Krithika Subramanian , PhD | Authors


Frontline Maintenance Therapy for Urothelial Cancer Emerges

December 30, 2020

After decades of dormancy, the therapeutic landscape of locally advanced/metastatic urothelial cancer underwent a paradigm shift—with multiple regulatory approvals of immune checkpoint inhibitors as second-line treatment—leading to changes in guideline-recommended management of patients in this setting.

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine

December 09, 2020

Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer, redirecting attention toward advances in biomarker testing methodologies.

Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations

December 27, 2019

The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.